金新农(002548) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥1,089,319,765.36, representing a 1.84% increase compared to ¥1,069,619,354.61 in the same period last year[5] - The net profit attributable to shareholders was -¥99,054,507.62, an improvement of 34.38% from -¥150,956,695.98 year-on-year[5] - Net loss for Q1 2023 was CNY 97,360,683.43, an improvement from a net loss of CNY 185,671,352.20 in Q1 2022, indicating a reduction in losses by about 47.7%[31] - The company reported a basic earnings per share of -0.12, an improvement from -0.17 in the same quarter last year[31] Cash Flow - The net cash flow from operating activities decreased by 260.23%, amounting to -¥171,744,228.72 compared to ¥107,186,922.95 in the previous year[5] - The net cash flow from operating activities was negative CNY 171,744,228.72, compared to a positive cash flow of CNY 107,186,922.95 in the previous year[32] - The cash inflow from investment activities was CNY 54,932,683.63, down from CNY 76,583,246.49 in the previous year[32] - In Q1 2023, the net cash flow from investment activities was -27,539,856.83 CNY, compared to -41,825,770.78 CNY in Q1 2022, indicating an improvement[33] - The total cash inflow from financing activities was 715,456,114.75 CNY, up from 620,713,418.28 CNY in the same period last year[33] - Cash outflow for debt repayment was 597,644,500.00 CNY, an increase from 525,650,000.00 CNY in Q1 2022[33] - The net increase in cash and cash equivalents was -199,250,472.65 CNY, contrasting with a positive increase of 6,002,837.92 CNY in Q1 2022[33] - The ending balance of cash and cash equivalents was 1,017,863,970.06 CNY, compared to 829,537,283.48 CNY at the end of Q1 2022[33] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,777,797,883.49, a decrease of 2.87% from ¥6,978,411,394.20 at the end of the previous year[5] - Current assets decreased to CNY 2,192,894,347.78 from CNY 2,373,426,204.75, primarily due to a reduction in cash and inventory[27] - The company's cash and cash equivalents were CNY 1,087,133,603.17, down from CNY 1,284,162,746.03 at the start of the year, reflecting a decrease of approximately 15.3%[26] - Total liabilities decreased to CNY 4,692,403,780.55 from CNY 4,796,901,729.41, indicating a reduction of about 2.2%[28] - Short-term borrowings rose to CNY 1,524,709,412.71 from CNY 1,297,351,370.41, an increase of approximately 17.5%[28] - The company's equity increased slightly to CNY 2,085,394,102.94 from CNY 2,181,509,664.79, reflecting a decrease of about 4.4%[28] Income and Expenses - Other income increased by 132.97% year-on-year, mainly due to an increase in government subsidies received[12] - Other income increased to CNY 6,429,751.64 from CNY 2,759,914.03, marking a growth of approximately 132.3%[30] - Total operating costs decreased to CNY 1,165,193,523.25 from CNY 1,200,696,346.51, representing a reduction of approximately 2.9%[30] - Research and development expenses decreased to CNY 11,947,369.01 from CNY 15,766,093.01, a decline of approximately 24.5%[30] - The company recorded a decrease in sales expenses to CNY 14,346,007.36 from CNY 13,804,184.15, reflecting a slight increase of about 3.9%[30] Accounts Receivable and Impairment - Accounts receivable increased by 140.60% compared to the beginning of the period, primarily due to an increase in receivables from feed sales[9] - Credit impairment losses increased by 378.39% compared to the same period last year, primarily due to an increase in accounts receivable and higher bad debt provisions[13] - Accounts receivable increased significantly to CNY 161,663,653.76 from CNY 67,191,298.46, representing a growth of approximately 140.4%[26] Other Information - The company reported a 79.99% decrease in non-operating expenses year-on-year, mainly due to a reduction in the death of productive biological assets[14] - The company has not disclosed any new product developments or market expansion strategies in the current report[25] - The company did not undergo an audit for the Q1 2023 report[34]